...
首页> 外文期刊>Journal of drug targeting >Recombinant alpha-fetoprotein C-terminal fragment: the new recombinant vector for targeted delivery.
【24h】

Recombinant alpha-fetoprotein C-terminal fragment: the new recombinant vector for targeted delivery.

机译:重组甲胎蛋白C末端片段:用于靶向递送的新型重组载体。

获取原文
获取原文并翻译 | 示例
           

摘要

The specific receptor of alpha-fetoprotein (AFP) is a universal tumor marker, being expressed on the surface of many tumor cells, but not in normal human tissues. AFP enters the cell by receptor-mediated endocytosis; its receptor-binding site is hypothetically localized in the third domain of AFP. A recombinant C-terminal AFP fragment, which contains all the third and a part of the second domains of hAFP, was produced. This AFP fragment was bound specifically to the AFP receptor on the surface of tumor cells and was accumulated by them with the same efficiency as the full-size hAFP. Similar to hAFP, the recombinant C-terminal fragment inhibited the estradiol-induced growth of hormone-dependent MCF-7 cells in vitro. Hence, the recombinant C-terminal AFP fragment can be used as a protein vector for the targeted delivery of cytostatic drugs to tumor cells.
机译:甲胎蛋白(AFP)的特异性受体是一种通用的肿瘤标志物,在许多肿瘤细胞的表面表达,但在正常的人体组织中却不表达。 AFP通过受体介导的内吞作用进入细胞;假设其受体结合位点位于AFP的第三个结构域。产生了包含hAFP的所有第三和部分第二结构域的重组C末端AFP片段。该AFP片段特异性结合至肿瘤细胞表面上的AFP受体,并被它们以与全尺寸hAFP相同的效率积累。与hAFP相似,重组C末端片段在体外抑制雌二醇诱导的激素依赖性MCF-7细胞的生长。因此,重组的C末端AFP片段可以用作蛋白质载体,用于将细胞抑制药物靶向递送至肿瘤细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号